上皮源性肿瘤软脑膜转移患者脑脊液中循环肿瘤细胞数量的额外预后价值
该单中心回顾性研究连续纳入103例上皮源性肿瘤软脑膜转移患者,于诊断时用基于上皮细胞黏附分子(EpCAM)的免疫流式细胞术检测脑脊液循环肿瘤细胞。中位生存129天;多变量模型中脑脊液循环肿瘤细胞数量具有显著附加预后价值(HR=1.86,95%CI=1.26-2.76,似然比检验P=0.003)。
要点
- 脑脊液循环肿瘤细胞数量在多变量模型中对软脑膜转移生存预测有显著附加价值(HR=1.86,95%CI=1.26-2.76,P=0.003)。
- 研究纳入103例上皮源性肿瘤软脑膜转移患者,60%为NSCLC、29%为乳腺癌,中位生存129天。
- 作者认为评估软脑膜转移患者预后时应考虑脑脊液循环肿瘤细胞数量。
核心结论
- 作者认为,用EpCAM免疫流式细胞术检测的脑脊液循环肿瘤细胞数量,对其他已知临床生存预测因素具有额外预后价值。
- 作者认为评估软脑膜转移患者预后时应考虑脑脊液循环肿瘤细胞数量。
研究设计与样本
- 单中心回顾性研究,纳入连续的上皮源性肿瘤软脑膜转移患者队列。
- 于软脑膜转移诊断时用基于EpCAM的免疫流式细胞术检测脑脊液循环肿瘤细胞。
- 按EANO-ESMO标准将患者诊断为可能、很可能或确诊软脑膜转移,共纳入103例符合条件患者(60%为NSCLC,29%为乳腺癌)。
主要发现
- 中位生存期为129天。
- 脑脊液循环肿瘤细胞数量在多变量预后模型中具有显著附加预后价值(HR=1.86,95%CI=1.26-2.76,含与不含循环肿瘤细胞模型的似然比检验P=0.003)。
临床怎么用
- 作者认为评估软脑膜转移患者预后时应考虑脑脊液循环肿瘤细胞数量。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Leptomeningeal metastases (LM) from solid tumors are described in up to 10 % of patients, and median survival rates are low. Advanced techniques for circulating tumor cell enumeration in cerebrospinal fluid (CSF) can help in diagnosing patients with LM but also could have value in prognostication. Our aim was to investigate whether the number of circulating tumor cells (CTCs) in CSF are of added value in survival prediction in LM patients. METHODS: We performed a single-center retrospective study in a cohort of consecutive patients with LM from epithelial tumors. Circulating tumor cells in CSF were measured by an Epithelial Cell Adhesion Molecule (EpCAM)-based immunoflow cytometry method at LM diagnosing. The added prognostic value of the number of CTCs in CSF on top of known clinical prognostic factors for LM was assessed. We compared Cox proportional hazards regression models with and without CTCs by discriminative performance measures. RESULTS: We included 103 eligible patients with epithelial tumors (60 % NSCLC, 29 % breast cancer), who were diagnosed with either possible, probable, or confirmed LM according to EANO-ESMO criteria. Median survival was 129 days. CTC numbers in CSF were of significant added prognostic value in a multivariable prognostic model (HR = 1.86, 95 % CI = 1.26-2.76, likelihood ratio test p-value=0.003 for models with CTCs versus without CTCs). CONCLUSION: Our findings indicate that the number of CTCs in CSF, as measured by EpCAM immunoflow cytometry, are of additional prognostic value to other well-known clinical predictors of survival in LM. The number of CTCs in CSF should be taken in account when assessing the prognosis of patients with LM.
引用
- van Kessel E, Woerdman N, Pluim D, et al. Added prognostic value of circulating tumor cell numbers in CSF of patients with leptomeningeal metastasis from epithelial tumors. Eur J Cancer. 2025. PMID: 40184847. doi:10.1016/j.ejca.2025.115377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。